Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Blow For Industry As GSK-Teva ‘Skinny Label’ Decision Upheld

Aug 06 2021

• By David Wallace

Chisel Carve Out Wood — Generic drug labeling carve-outs are once again in the spotlight. • Source: Alamy

Related Content

Generic ‘Skinny Labels’ Get Reprieve As Court Agrees To Rehear Teva/GSK Case

Feb 11 2021

AAM Steps Into GSK-Teva Case To Defend Carve-Outs

Dec 17 2020

US Court Offers Second Chance On GSK-Teva ‘Skinny Label’ Ruling

Feb 10 2021

Sandoz Keeps Tabs On Teva Skinny Label Ruling

Oct 28 2020

Teva Coreg Damages Reinstated As AAM Bemoans ‘Antithetical’ Ruling

Oct 07 2020

Hikma Fails To Nix Vascepa Induced Infringement Case Early On

Aug 04 2021

Related Companies

Teva Pharmaceutical Industries Ltd.

GSK plc

Hikma Pharmaceuticals plc

Amarin Corp plc

Additional Topics

United States Legal Issues Intellectual Property Regulation Generic Drugs BioPharmaceutical

More from Legal & IP

More from Pink Sheet

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.